<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1473">
  <stage>Registered</stage>
  <submitdate>18/07/2006</submitdate>
  <approvaldate>26/07/2006</approvaldate>
  <actrnumber>ACTRN12606000322538</actrnumber>
  <trial_identification>
    <studytitle>The efficacy of intranasal administration of Naloxone by paramedics for the successful treatment of suspected heroin overdose in the prehospital setting.</studytitle>
    <scientifictitle>The efficacy of intranasal administration of Naloxone by paramedics for the successful treatment of suspected heroin overdose in the prehospital setting.</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>Opiate Overdose</healthcondition>
    <conditioncode>
      <conditioncode1>Mental Health</conditioncode1>
      <conditioncode2>Addiction</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Randomisation to receive either intramuscular naloxone 2mg or intranasal naloxone 2mg via a mucosal atomisation device [MAD].  Subjects receive one dose only of intranasal naloxone before re-assessment at 10 minutes post treatment.  Subjects are given additional intramuscular Naloxone after 10 minutes if clinically necessary.
Duration of the study is likely to be 18 months, commencing 1st August 2006 and concluding 31st January 2008.</interventions>
    <comparator>Intranasal (IN) Naloxone is the intervention and Intramuscular (IM) Naloxone is the control. Patients in the control group received 2mg IM naloxone. Participants received only 1 dose of IM naloxone. After 10 minutes, patients without adequate response were administered secondary naloxone treatment [endpoint] via the IM route [2mg].</comparator>
    <control>Active</control>
    <interventioncode>Treatment: Devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Requirement for subsequent treatment with Naloxone</outcome>
      <timepoint>At 10 minutes from randomisation treatment.</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Time to adequate and effective spontaneous respirations.</outcome>
      <timepoint>10 minutes.</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to adequate consciousness.</outcome>
      <timepoint>10 minutes</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>All suspected opiate overdose victims in the prehospital setting to be treated by paramedics with naloxone will be included in this study, regardless of age or gender .Client unrousable i.e. GCS  less than 13.No major facial trauma/blocked nasal passages/epistaxis.</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Client rousable i.e. GCS Greater than 12.Major facial trauma/blocked nasal passages/epistaxis.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Conclealed envelope with randomisation advice enclosed.</concealment>
    <sequence>Simple randomisation by using a randomization table created by a computer software (i.e., computerised sequence generation).</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate>1/08/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>200</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>Department of Human Services, Australian Government.</primarysponsorname>
    <primarysponsoraddress>18/120 Spencer St
Melbourne Victoria 3000</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>Department of Human Services, Australian Government.</fundingname>
      <fundingaddress>18/120 Spencer St
Melbourne Victoria 3000</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine the effectiveness of concentrated intranasal naloxone compared to intramuscular naloxone for treatment by paramedics of respiratory depression due to suspected opiate overdose in the pre-hospital setting. Subjects are unconscious prior to study enrolment, and consent from individuals for study participation is not required.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Melbourne Health Research Directorate</ethicname>
      <ethicaddress />
      <ethicapprovaldate>20/02/2006</ethicapprovaldate>
      <hrec>2001.172</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
    <ethicscommitee>
      <ethicname>Monash University</ethicname>
      <ethicaddress />
      <ethicapprovaldate>5/12/2005</ethicapprovaldate>
      <hrec>2005/813MC</hrec>
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Debra Kerr</name>
      <address>The Joseph Epstein Centre for Emergency Medicine Research
Sunshine Hospital
176 Furlong Rd
St Albans VIC 3021</address>
      <phone>+61 3 83451027</phone>
      <fax>+61 3 83451019</fax>
      <email>Debbie.Kerr@wh.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Debra Kerr</name>
      <address>The Joseph Epstein Centre for Emergency Medicine Research
Sunshine Hospital
176 Furlong Rd
St Albans VIC 3021</address>
      <phone>+61 3 83451027</phone>
      <fax>+61 3 83451019</fax>
      <email>Debbie.Kerr@wh.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Debra Kerr</name>
      <address>JECEMR
Sunshine Hospital
176 Furlong Rd
St Albans Victoria 3021</address>
      <phone>+61 3 83451027</phone>
      <fax>+61 3 83451019</fax>
      <email>Debbie.Kerr@wh.org.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>